Supplementary Figure 1. Effect of vemurafenib, selumetinib, or E6201 on Cyclin D1 expression in exogenous MEK1-WT-positive or -negative A375 cells (A) Cells were treated with 3.3 μM vemurafenib, 1.1 μM selumetinib, or 1.1 μM E6201. Hoechst is a total cell stain. Azami-Green-positive cells represent exogenous MEK1-WT-expressing cells. Scale bar represents 100 μm. (B) Quantification of Cyclin D1 expression in exogenous MEK1-WT-positive or -negative cells after treatment with the test compounds.

Supplementary Figure 2. MAPK pathway inhibitory activity of the test compounds in G361.

Supplementary Figure 3. Effect of vemurafenib, selumetinib, or E6201 on Cyclin D1 expression in (A) exogenous MEK1-C121S-positive or -negative G361 cells and in (B) exogenous MEK1-WT-positive or -negative G361 cells.

Supplementary Figure 4. Cleavaged -PARP induction in A375 and G361 parental cells.